Arcturus Therapeutics (ARCT) Misses Q1 EPS by 411c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($0.52), $4.11 worse than the analyst estimate of $3.59. Revenue for the quarter came in at $29.38 million versus the consensus estimate of $205.21 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Ladybug Resource Group updates M&A program, holds early financing talks
• The New York Times Co. (NYT) call put ratio 2.3 calls to 1 put with a focus on February 220 calls as share price down 1.9%
• Charter Communications (CHTR) call put ratio 1.6 calls to 1 put as share price near low end of range